Company performance
Add to research
Current Price
as of Jun 18, 2025$19.80
P/E Ratio
N/A
Market Cap
$369.88M
Description
Add to research
AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA.
Metrics
Add to research
Overview
- HQWatertown, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerAVRO
- Price$19.8-3.46%
Trading Information
- Market cap$369.88M
- Float56.60%
- Average Daily Volume (1m)156,727
- Average Daily Volume (3m)206,306
- EPS-$7.31
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$15.91M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$17.94M
- EV$0.25M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B1.23
- Debt/Equity0.87
Documents
Add to research
SEC Filings
Factset Street Account